Trials / Completed
CompletedNCT01951235
A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes
A Dose-ranging, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes Mellitus.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 315 (actual)
- Sponsor
- Poxel SA · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety/tolerability of 4 doses of Imeglimin versus placebo. The study will be performed in subjects with type 2 diabetes either naive of treatment or previously treated with an oral monotherapy excluding thiazolidinedione.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imeglimin | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2013-09-26
- Last updated
- 2015-08-13
Locations
1 site across 1 country: Latvia
Source: ClinicalTrials.gov record NCT01951235. Inclusion in this directory is not an endorsement.